Medications can shrink nasal polyps. Surgery is often needed to remove them, but they can grow back unless the underlying cause is addressed.

A decision to proceed with nasal polyp surgery was recorded in just 0.5% of tezepelumab-treated patients compared to 22.1% in the placebo group (hazard ratio, 0.02). Systemic glucocorticoid use ...

Current treatments involve intranasal corticosteroids, short-term systemic corticosteroids for symptom exacerbations, and surgical removal of nasal polyps. Type 2 inflammation is driven by ...

In this randomized controlled trial, among patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, tezepelumab more effectively reduced nasal polyp size and sinonasal symptoms ...

The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

A new CT-scan-based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to ...

The need for systemic corticosteroids fell by 88%, and the need for surgery fell by 98%. Nasal polyp and congestion scores fell, along with loss of smell and total symptom scores. SAN DIEGO ...

Medication. Certain medications may shrink the polyps and lessen symptoms, however the symptoms typically recur once the medication is stopped. Surgical removal. Endometrial polyps can be removed ...

During the follow-up, 15.9% of patients required at least one revision surgery. The probability of revision sinus surgery ...

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases. Even after surgical treatment, the recurrence rate of CRSwNP remains high, ranging from 20 to 60 percent ...